Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABBV.MX
STRONG BUYAbbVie Inc. · Healthcare · United States · $438.5B · Avg Vol: $95K/d
82
StockRankGet insider-trade alerts
Q
72
V
36
M
67
P/E (TTM)
123.5x
ROE
—
D/E
—
Dividend %
2.7%
COMPANY DESCRIPTION
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.1B | 54.3B | 56.3B | 61.2B | 1.8% | 62.8B | 67.2B | 72.7B | 9.1% |
| EPS | 6.69 | 2.75 | 2.42 | 2.39 | -29.0% | 2.03 | — | — | — |
| Shares | 1.8B | 1.8B | 1.8B | 1.8B | +1.4% | 1.8B | — | — | — |
| Debt | 63.3B | 59.4B | 67.1B | 67.5B | 2.2% | 72.9B | — | — | — |
| Equity | 17.3B | 10.4B | 3.3B | -3.3B | -56.1% | — | — | — | — |
| Op CF | 24.9B | 22.8B | 18.8B | 19.0B | -8.6% | 21.2B | — | — | — |
| Inv CF | -623.0M | -2.0B | -20.8B | -6.6B | — | — | — | — | — |
| Fin CF | -24.8B | -17.2B | -5.2B | -12.7B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+17.4%
SMA 50SMA 200
Close
$251.33
RSI (14)
83.0
52W High
$260.19
From 52W High
1.0%
SCORE BREAKDOWN
Quality
72
ROIC
10.5%74.9
ROE
neg eq95.0
GP/Assets
33.8%72.1
Op. Margin
32.2%93.5
FCF/Assets
13.3%91.8
Piotroski
782.9
Int. Cover
3.3x45.7
D/E Ratio
neg eq45.7
Current Ratio
0.80x5.7
Value
36
P/E (TTM)
123.5x7.6
EV/EBITDA
15.0x44.7
P/FCF
24.6x49.7
P/B
-3.8x25.0
P/S
7.1x33.4
Div Yield
2.7%61.0
Momentum
67
52W High %
97%93.3
RS 6M
4%74.0
SMA 50/200
0.98x60.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-46%11.3
FUNDAMENTALS
Market Cap
$438.5B
P/E (Forward)
—
Gross Margin
72.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABBV.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABBV.MX | AbbVie Inc.(you) | $438.5B | 82 | STRONG BUY |
| AZN | AstraZeneca PLC | $292.2B | 83 | STRONG BUY |
| NOVN.SW | Novartis AG | $297.7B | 85 | STRONG BUY |
| JNJ.DE | Johnson & Johnson | $609.8B | 77 | BUY |
| RO.SW | Roche Holding AG | $336.1B | 93 | STRONG BUY |
| NOVO-B.CO | Novo Nordisk A/S | $214.5B | 84 | STRONG BUY |
| AMGN | Amgen Inc. | $193.4B | 83 | STRONG BUY |
| MRK | Merck & Co., Inc. | $317.8B | 93 | STRONG BUY |
| LLY | Eli Lilly and Company | $1.1T | 82 | STRONG BUY |
| PFE | Pfizer Inc. | $138.4B | 92 | STRONG BUY |
Peer medians: ROE 2.7% · P/E 22.8x · Gross margin 47.5%